PrEVENITY™ (romosozumab injection)

Romosozumab, a sclerostin inhibitor, is the first new approach to the treatment of osteoporosis and fracture risk in almost a decade.
Romosozumab (PrEVENITY™) significantly and rapidly (over 12 months) increases BMD in both the lumbar spine and total hip, and in both trabecular and cortical bone, leading to an increase in bone strength and reduced risk of fracture. In clinical trials, romosozumab shows better results than other treatments.

Adverse reactions in contrast to other treatments were equally balanced with the exception of cardiovascular events where a slightly increased risk has been shown.

Other PrEVENITY™ news: Health Canada has provided a Notice of Compliance (NOC) to PrEVENITY™ (romosozumab) Indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture.


Osteoporosis Canada is encouraged to see additional treatments become available for Canadians who are at high risk of fracture from osteoporosis. If you are at high risk of fracture, the benefits of taking a bone drug can outweigh the associated risks. However, a full consultation with your doctor should be conducted prior to starting treatment.